Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Doxazosin
Drug ID BADD_D00718
Description Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin].[A180661] Because of its long-lasting effects, doxazosin can be administered once a day.[A180649] It is marketed by Pfizer and was initially approved by the FDA in 1990.[L7285]
Indications and Usage For treatment and management of mild to moderate hypertension and urinary obstruction symptoms caused by BPH.
Marketing Status Prescription; Discontinued
ATC Code C02CA04
DrugBank ID DB00590
KEGG ID D07874
MeSH ID D017292
PubChem ID 3157
TTD Drug ID D03MIR
NDC Product Code 0049-2614; 23155-092; 68071-4272; 50090-3927; 42291-259; 70518-2183; 68071-4892; 16729-415; 68382-784; 68788-7149; 70518-1560; 50090-0704; 0049-2040; 70518-1804; 70934-362; 68071-5153; 16729-414; 65427-018; 71610-043; 66267-377; 50090-5773; 70771-1112; 50090-0734; 0904-5523; 16729-213; 60505-0093; 68788-7328; 60505-0094; 68084-862; 43063-739; 59762-2420; 16729-211; 71335-0309; 23155-095; 63629-7891; 68382-785; 59762-2410; 50090-2153; 59762-2480; 71610-628; 68084-836; 71335-0002; 55154-7996; 0049-2410; 70934-921; 71610-153; 50090-0701; 23155-094; 68071-3298; 42291-258; 70771-1113; 0049-2512; 0904-5522; 68084-851; 50090-4000; 50090-4004; 23155-093; 42291-260; 60505-0096; 68382-786; 0904-5524; 50090-5540; 60505-0095; 50090-0706; 50090-3987; 68071-4273; 72189-117; 71610-160; 70934-366; 68382-783; 70771-1114; 70771-1115
Synonyms Doxazosin | Novo-Doxazosin | Novo Doxazosin | Uriduct | Alfamedin | Apo-Doxazosin | Apo Doxazosin | Cardura | Cardular | Zoxan | Carduran | Carduran Neo | Neo, Carduran | Diblocin | Doxa-Puren | Doxa Puren | Doxacor | DoxaUro | Doxagamma | Doxamax | Doxatensa | Doxazomerck | Doxazosin AL | Doxazosin Apogepha | Doxazosin AZU | Doxazosin beta | Doxazosin findusFit | Doxazosin Heumann | Doxazosin Klast | Doxazosin Mesylate | Mesylate, Doxazosin | 1 (4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine | Doxazosin Monohydrochloride | Monohydrochloride, Doxazosin | Doxazosin Stada | Doxazosin Von Ct | Ct, Doxazosin Von | Von Ct, Doxazosin | Doxazosin-ratiopharm | Doxazosin ratiopharm | ratio-Doxazosin | ratio Doxazosin | Doxazosina Ratiopharm | Ratiopharm, Doxazosina | Doxazosin-Wolff | Doxazosin Wolff | Doxazosina Alter | Doxazosina Cinfa | Doxazosina Combino Pharm | Doxazosina Geminis | Doxazosina Normon | Doxazosina Pharmagenus | Doxazosina Ur | Gen-Doxazosin | Gen Doxazosin | Jutalar | MTW-Doxazosin | MTW Doxazosin | Progandol Neo | UK-33274 | UK 33274 | UK33274
Chemical Information
Molecular Formula C23H25N5O5
CAS Registry Number 74191-85-8
SMILES COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Subarachnoid haemorrhage17.08.01.010; 12.01.10.011; 24.07.04.004--Not Available
Sudden death08.04.01.003; 02.03.04.013--
Swelling08.01.03.0150.000727%Not Available
Swollen tongue23.04.01.014; 10.01.05.015; 07.14.02.0030.000485%Not Available
Syncope24.06.02.012; 17.02.04.008; 02.01.02.0080.009450%
Tachycardia02.03.02.0070.001212%Not Available
Tendon disorder15.07.01.002--Not Available
Tension19.06.02.005--Not Available
Thinking abnormal17.02.05.023; 19.10.03.0010.000727%Not Available
Thirst14.03.02.007; 08.01.09.021--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue disorder07.14.01.002--Not Available
Tooth disorder07.09.05.001--Not Available
Tooth erosion07.09.05.0020.000485%Not Available
Tooth hypoplasia07.09.08.003; 03.04.01.002--Not Available
Tremor17.01.06.0020.001696%
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary incontinence20.02.02.010; 17.05.01.0080.001454%
Urinary retention20.02.02.0110.001212%
Urinary tract infection20.08.02.001; 11.01.14.004--
Urine abnormality20.02.01.013--Not Available
Urticaria23.04.02.001; 10.01.06.0010.002423%
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Ventricular fibrillation02.03.04.0080.000727%
Ventricular tachycardia02.03.04.0100.000485%
Vertigo17.02.12.002; 04.04.01.0030.002423%
Viral infection11.05.04.001--Not Available
Vision blurred17.17.01.010; 06.02.06.0070.002665%
Visual field defect06.02.07.003; 17.17.01.001--Not Available
The 9th Page    First    Pre   9 10 11    Next   Last    Total 11 Pages